You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuinapril
Accession NumberDB00881  (APRD00523)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionQuinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Quinapril may be used to treat essential hypertension and congestive heart failure.
Structure
Thumb
Synonyms
Quinapril
Quinaprilum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accupriltablet, film coated5 mg/1oralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupriltablet, film coated40 mg/1oralbryant ranch prepack1991-11-19Not applicableUs
Accupriltablet, film coated10 mg/1oralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupriltablet, film coated10 mg/1oralCardinal Health1991-11-19Not applicableUs
Accupriltablet, film coated20 mg/1oralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupriltablet, film coated20 mg/1oralCardinal Health1991-11-19Not applicableUs
Accupriltablet, film coated40 mg/1oralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupril 5mg Tabtablet5 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Accupril Tab 10mgtablet10 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Accupril Tab 20mgtablet20 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Accupril Tab 40mgtablet40 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Gd-quinapriltablet40 mgoralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinapriltablet5 mgoralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinapriltablet10 mgoralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinapriltablet20 mgoralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
PMS-quinapriltablet40 mgoralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinapriltablet5 mgoralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinapriltablet10 mgoralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinapriltablet20 mgoralPharmascience Inc2013-11-18Not applicableCanada
Quinapriltablet40 mgoralPro Doc Limitee2013-11-28Not applicableCanada
Quinapriltablet5 mgoralPro Doc Limitee2013-11-28Not applicableCanada
Quinapriltablet10 mgoralPro Doc Limitee2013-11-28Not applicableCanada
Quinapriltablet20 mgoralPro Doc Limitee2013-11-28Not applicableCanada
Quinapril Hydrochloridetablet, film coated5 mg/1oralGreenstone LLC1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated10 mg/1oralGreenstone LLC1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated5 mg/1oralCarilion Materials Management1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated20 mg/1oralGreenstone LLC1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated10 mg/1oralCarilion Materials Management1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated40 mg/1oralGreenstone LLC1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated20 mg/1oralCarilion Materials Management1991-11-19Not applicableUs
Ran-quinapriltablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-quinapriltablet5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-quinapriltablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-quinapriltablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-quinapriltablet20 mgoralApotex Inc2013-07-02Not applicableCanada
Apo-quinapriltablet40 mgoralApotex Inc2013-07-02Not applicableCanada
Apo-quinapriltablet5 mgoralApotex Inc2013-07-02Not applicableCanada
Apo-quinapriltablet10 mgoralApotex Inc2013-07-02Not applicableCanada
Quinapriltablet40 mg/1oralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
Quinapriltablet, film coated20 mg/1oralAurobindo Pharma Limited2013-04-29Not applicableUs
Quinapriltablet5 mg/1oralAv Kare, Inc.2012-08-022016-01-21Us
Quinapriltablet40 mg/1oralLupin Pharmaceuticals, Inc.2014-08-01Not applicableUs
Quinapriltablet, film coated20 mg/1oralPhysicians Total Care, Inc.2005-03-03Not applicableUs
Quinapriltablet, film coated10 mg/1oralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
Quinapriltablet5 mg/1oralRebel Distributors Corp2010-02-26Not applicableUs
Quinapriltablet5 mg/1oralAv Pak2014-08-052016-03-11Us
Quinapriltablet, film coated20 mg/1oralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
Quinapriltablet10 mg/1oralBlue Point Laboratories2014-02-25Not applicableUs
Quinapriltablet20 mg/1oralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
Quinapriltablet40 mg/1oralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
Quinapriltablet5 mg/1oralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
Quinapriltablet, film coated40 mg/1oralbryant ranch prepack2010-02-25Not applicableUs
Quinapriltablet10 mg/1oralAv Kare, Inc.2012-08-022016-01-21Us
Quinapriltablet40 mg/1oralCardinal Health2012-01-20Not applicableUs
Quinapriltablet, film coated40 mg/1oralAurobindo Pharma Limited2013-04-29Not applicableUs
Quinapriltablet10 mg/1oralRebel Distributors Corp2010-02-26Not applicableUs
Quinapriltablet5 mg/1oralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
Quinapriltablet, film coated10 mg/1oralPhysicians Total Care, Inc.2005-03-07Not applicableUs
Quinapriltablet, film coated20 mg/1oralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
Quinapriltablet5 mg/1oralBlue Point Laboratories2014-02-25Not applicableUs
Quinapriltablet10 mg/1oralAv Pak2014-08-052016-03-11Us
Quinapriltablet, film coated40 mg/1oralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
Quinapriltablet10 mg/1oralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
Quinapriltablet, film coated5 mg/1oralAurobindo Pharma Limited2013-04-29Not applicableUs
Quinapriltablet40 mg/1oralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
Quinapriltablet20 mg/1oralAv Kare, Inc.2012-08-022016-01-21Us
Quinapriltablet, film coated5 mg/1oralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
Quinapriltablet40 mg/1oralBlue Point Laboratories2014-02-25Not applicableUs
Quinapriltablet5 mg/1oralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
Quinapriltablet10 mg/1oralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
Quinapriltablet, film coated40 mg/1oralPhysicians Total Care, Inc.2007-11-28Not applicableUs
Quinapriltablet, film coated40 mg/1oralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
Quinapriltablet10 mg/1oralProficient Rx LP2012-01-20Not applicableUs
Quinapriltablet40 mg/1oralBlue Point Laboratories2014-07-18Not applicableUs
Quinapriltablet20 mg/1oralAv Pak2014-08-052016-03-11Us
Quinapriltablet20 mg/1oralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
Quinapriltablet, film coated10 mg/1oralAurobindo Pharma Limited2013-04-29Not applicableUs
Quinapriltablet40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-02-26Not applicableUs
Quinapriltablet40 mg/1oralAv Kare, Inc.2012-08-022016-01-21Us
Quinapriltablet, film coated10 mg/1oralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
Quinapriltablet20 mg/1oralBlue Point Laboratories2014-02-25Not applicableUs
Quinapriltablet10 mg/1oralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
Quinapriltablet20 mg/1oralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
Quinapriltablet, film coated5 mg/1oralPhysicians Total Care, Inc.2005-07-22Not applicableUs
Quinapriltablet, film coated20 mg/1oralbryant ranch prepack2010-02-25Not applicableUs
Quinapriltablet, film coated5 mg/1oralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
Quinapriltablet20 mg/1oralAmerican Health Packaging2015-09-15Not applicableUs
Quinapriltablet40 mg/1oralAv Pak2014-08-052016-03-11Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AccuprinPfizer (Italy)
AccuproPfizer (Austria, Denmark, Finland, Germany, Hungary, Ireland, Sweden, Switzerland, United Kingdom, Ukraine), Godecke (Czech Republic, Germany, Poland, Russia), Parke, Davis (Germany)
AcequinNot Available
AcuitelNot Available
KorecNot Available
QuinazilNot Available
Brand mixtures
NameLabellerIngredients
AccureticParke Davis Div Of Pfizer Inc
Accuretic 10/12.5 mgPfizer Canada Inc
Accuretic 20/12.5 mgPfizer Canada Inc
Accuretic 20/25 mgPfizer Canada Inc
Apo-quinapril/hctzApotex Inc
Gd-quinapril HctzGenmed A Division Of Pfizer Canada Inc
Quinapril HCl and HydrochlorothiazideGavis Pharmaceuticals, LLC.
Quinapril Hydrochloride and HydrochlorothiazideMylan Pharmaceuticals Inc.
Quinapril Hydrochloride/hydrochlorothiazideLake Erie Medical DBA Quality Care Products LLC
Salts
Name/CASStructureProperties
Quinapril Hydrochloride
82586-55-8
Thumb
  • InChI Key: IBBLRJGOOANPTQ-JKVLGAQCSA-N
  • Monoisotopic Mass: 474.192149819
  • Average Mass: 474.977
DBSALT000465
Categories
UNIIRJ84Y44811
CAS number85441-61-8
WeightAverage: 438.5161
Monoisotopic: 438.21547208
Chemical FormulaC25H30N2O5
InChI KeyInChIKey=JSDRRTOADPPCHY-HSQYWUDLSA-N
InChI
InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[[email protected]]1C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Tetrahydroisoquinoline
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
PharmacodynamicsQuinapril is a nonpeptide, non-sulfhydryl prodrug that is deesterified to quinaprilat (quinapril diacid), its major active metabolite following oral administration. Quinaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of quinaprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Quinaprilat, the principle active metabolite of quinapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Quinaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
Related Articles
AbsorptionPeak plasma concentrations of quinapril occur within one hour following oral administration. The extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.
Volume of distributionNot Available
Protein binding97%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Quinapril
Not Available
QuinaprilatDetails
Route of eliminationQuinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose
Half lifeElimination half life is 2 hours with a prolonged terminal phase of 25 hours.
ClearanceNot Available
ToxicityOverdose may lead to severe hypotension. LD50=1739mg/kg (orally in mice). The most common adverse effects observed in controlled clinical trials were dizziness, cough, chest pain, dyspnea, fatigue, and nausea/vomiting.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Quinapril Metabolism PathwayDrug metabolismSMP00596
Quinapril Action PathwayDrug actionSMP00153
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5597
Blood Brain Barrier-0.9409
Caco-2 permeable-0.8208
P-glycoprotein substrateSubstrate0.8895
P-glycoprotein inhibitor IInhibitor0.7344
P-glycoprotein inhibitor IIInhibitor0.5869
Renal organic cation transporterNon-inhibitor0.8258
CYP450 2C9 substrateNon-substrate0.8594
CYP450 2D6 substrateNon-substrate0.8412
CYP450 3A4 substrateSubstrate0.5356
CYP450 1A2 substrateNon-inhibitor0.8597
CYP450 2C9 inhibitorNon-inhibitor0.6832
CYP450 2D6 inhibitorNon-inhibitor0.8636
CYP450 2C19 inhibitorNon-inhibitor0.6016
CYP450 3A4 inhibitorInhibitor0.5347
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5162
Ames testNon AMES toxic0.9091
CarcinogenicityNon-carcinogens0.9294
BiodegradationNot ready biodegradable0.9596
Rat acute toxicity2.2690 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9763
hERG inhibition (predictor II)Inhibitor0.7176
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer pharmaceuticals ltd
  • Actavis totowa llc
  • Apotex inc
  • Genpharm inc
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral40 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral5 mg
Tabletoral10 mg
Tabletoral20 mg
Tabletoral40 mg
Tablet, film coatedoral
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral5 mg/1
Tabletoral
Prices
Unit descriptionCostUnit
Accupril 10 mg tablet2.02USD tablet
Accupril 20 mg tablet2.02USD tablet
Accupril 40 mg tablet2.02USD tablet
Accupril 5 mg tablet2.02USD tablet
Quinapril 10 mg tablet1.57USD tablet
Quinapril 20 mg tablet1.57USD tablet
Quinapril 40 mg tablet1.57USD tablet
Quinapril 5 mg tablet1.57USD tablet
Quinapril HCl 10 mg tablet1.27USD tablet
Quinapril HCl 20 mg tablet1.27USD tablet
Quinapril HCl 40 mg tablet1.27USD tablet
Quinapril HCl 5 mg tablet1.27USD tablet
Quinaretic 10-12.5 mg tablet1.27USD tablet
Quinaretic 20-12.5 mg tablet1.27USD tablet
Quinaretic 20-25 mg tablet1.27USD tablet
Accupril 10 mg Tablet0.96USD tablet
Accupril 20 mg Tablet0.96USD tablet
Accupril 40 mg Tablet0.96USD tablet
Accupril 5 mg Tablet0.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1331615 No1994-08-232011-08-23Canada
CA2023089 No2003-01-142010-08-10Canada
US5684016 No1995-05-042015-05-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point120-130 °CNot Available
water solubility1 mg/LNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0085 mg/mLALOGPS
logP1.39ALOGPS
logP1.96ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.7ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity119.96 m3·mol-1ChemAxon
Polarizability47.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Om P. Goel, Uldis Krolls, “Crystalline quinapril and a process for producing the same.” U.S. Patent US4761479, issued August, 1982.

US4761479
General References
  1. Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, Lerakis S, Helmy T: Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care. 2004 Jul;27(7):1712-5. [PubMed:15220251 ]
  2. Kieback AG, Felix SB, Reffelmann T: Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. [PubMed:19761414 ]
  3. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS: The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001 May 1;87(9):1058-63. [PubMed:11348602 ]
  4. Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J: Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol. 2004 Feb;44(2):150-7. [PubMed:14747423 ]
  5. Valles Prats M, Matas Serra M, Bronsoms Artero J, Mate Benito G, Torguet Escuder P, Mauri Nicolas JM: Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Kidney Int Suppl. 1996 Jun;55:S104-6. [PubMed:8743525 ]
  6. Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ, van Gilst WH: Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):130-4. [PubMed:15526248 ]
  7. Yamada S, Muraoka I, Kato K, Hiromi Y, Takasu R, Seno H, Kawahara H, Nabeshima T: Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull. 2003 Jun;26(6):872-5. [PubMed:12808303 ]
External Links
ATC CodesC09AA06C09BA06
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Quinapril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Quinapril.
AcebutololQuinapril may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Quinapril.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Quinapril.
AdapaleneThe risk or severity of adverse effects can be increased when Quinapril is combined with Adapalene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Quinapril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Quinapril.
AliskirenQuinapril may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Quinapril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Quinapril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Quinapril.
AlprenololAlprenolol may increase the hypotensive activities of Quinapril.
AmbrisentanQuinapril may increase the hypotensive activities of Ambrisentan.
AmifostineQuinapril may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Quinapril.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Quinapril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Quinapril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Quinapril.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Quinapril.
AmlodipineAmlodipine may increase the hypotensive activities of Quinapril.
AmobarbitalAmobarbital may increase the hypotensive activities of Quinapril.
Amyl NitriteThe risk or severity of adverse effects can be increased when Quinapril is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Quinapril is combined with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Quinapril is combined with Apraclonidine.
ApremilastThe risk or severity of adverse effects can be increased when Quinapril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Quinapril.
ArdeparinArdeparin may increase the hyperkalemic activities of Quinapril.
AripiprazoleAripiprazole may increase the hypotensive activities of Quinapril.
AtenololAtenolol may increase the hypotensive activities of Quinapril.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Quinapril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Quinapril.
AzapropazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Azapropazone.
AzathioprineQuinapril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Quinapril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Quinapril is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Quinapril is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Quinapril.
BemiparinBemiparin may increase the hyperkalemic activities of Quinapril.
BenazeprilBenazepril may increase the hypotensive activities of Quinapril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Quinapril.
BenmoxinBenmoxin may increase the hypotensive activities of Quinapril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Benoxaprofen.
BepridilQuinapril may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Quinapril.
BethanidineBethanidine may increase the hypotensive activities of Quinapril.
BimatoprostQuinapril may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Quinapril.
BoceprevirThe serum concentration of Quinapril can be decreased when it is combined with Boceprevir.
BosentanBosentan may increase the hypotensive activities of Quinapril.
BretyliumQuinapril may increase the hypotensive activities of Bretylium.
BrimonidineQuinapril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Quinapril.
BromfenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Quinapril.
BumetanideThe risk or severity of adverse effects can be increased when Quinapril is combined with Bumetanide.
BupranololQuinapril may increase the hypotensive activities of Bupranolol.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Quinapril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Quinapril.
CanagliflozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Quinapril.
CandoxatrilCandoxatril may increase the hypotensive activities of Quinapril.
CaptoprilQuinapril may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Quinapril can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Quinapril.
CarprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Quinapril.
CarvedilolQuinapril may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Quinapril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Celecoxib.
CeliprololQuinapril may increase the hypotensive activities of Celiprolol.
CertoparinCertoparin may increase the hyperkalemic activities of Quinapril.
ChloroquineThe risk or severity of adverse effects can be increased when Quinapril is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Quinapril.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Quinapril.
CilazaprilQuinapril may increase the hypotensive activities of Cilazapril.
CiprofloxacinQuinapril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Quinapril.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Quinapril.
ClevidipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Quinapril.
ClonidineClonidine may increase the hypotensive activities of Quinapril.
ClonixinThe risk or severity of adverse effects can be increased when Quinapril is combined with Clonixin.
CryptenamineCryptenamine may increase the hypotensive activities of Quinapril.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Quinapril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Quinapril.
CyclothiazideCyclothiazide may increase the hypotensive activities of Quinapril.
D-LimoneneThe risk or severity of adverse effects can be increased when Quinapril is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Quinapril.
DapagliflozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Quinapril.
DebrisoquinQuinapril may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Quinapril.
DeserpidineQuinapril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Quinapril.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quinapril.
DiazoxideDiazoxide may increase the hypotensive activities of Quinapril.
DiclofenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenamide.
DiflunisalThe risk or severity of adverse effects can be increased when Quinapril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Quinapril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Quinapril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Quinapril.
DiltiazemDiltiazem may increase the hypotensive activities of Quinapril.
DinutuximabThe risk or severity of adverse effects can be increased when Quinapril is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Dipyridamole.
DorzolamideDorzolamide may increase the hypotensive activities of Quinapril.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Quinapril.
DoxazosinDoxazosin may increase the hypotensive activities of Quinapril.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Quinapril.
DrospirenoneQuinapril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Droxicam.
DuloxetineQuinapril may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Quinapril.
EfonidipineQuinapril may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Quinapril.
EnalaprilatQuinapril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Quinapril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Quinapril.
EpirizoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Quinapril.
EplerenoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Eplerenone.
EpoprostenolQuinapril may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Quinapril.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Quinapril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Quinapril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Quinapril.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Quinapril.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Quinapril.
Etacrynic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Quinapril is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Quinapril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Quinapril is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Quinapril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Quinapril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Quinapril.
exisulindThe risk or severity of adverse effects can be increased when Quinapril is combined with exisulind.
FelodipineQuinapril may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Quinapril is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Quinapril.
FenoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Quinapril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Quinapril is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Flurbiprofen.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Quinapril.
FosinoprilFosinopril may increase the hypotensive activities of Quinapril.
FurazolidoneFurazolidone may increase the hypotensive activities of Quinapril.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Quinapril.
GarlicThe serum concentration of Quinapril can be decreased when it is combined with Garlic.
GuanabenzGuanabenz may increase the hypotensive activities of Quinapril.
GuanadrelGuanadrel may increase the hypotensive activities of Quinapril.
GuanethidineQuinapril may increase the hypotensive activities of Guanethidine.
GuanfacineQuinapril may increase the hypotensive activities of Guanfacine.
HeparinHeparin may increase the hyperkalemic activities of Quinapril.
HexamethoniumQuinapril may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Quinapril.
HMPL-004The risk or severity of adverse effects can be increased when Quinapril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Quinapril.
HydralazineQuinapril may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideQuinapril may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Quinapril.
IbuprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Quinapril is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Quinapril.
IcatibantThe risk or severity of adverse effects can be increased when Quinapril is combined with Icatibant.
IloprostIloprost may increase the hypotensive activities of Quinapril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Quinapril.
IndapamideIndapamide may increase the hypotensive activities of Quinapril.
IndenololQuinapril may increase the hypotensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Quinapril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Indoprofen.
IndoraminQuinapril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Quinapril.
IproniazidIproniazid may increase the hypotensive activities of Quinapril.
IrbesartanQuinapril may increase the hypotensive activities of Irbesartan.
IronThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Quinapril.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Quinapril is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Quinapril.
KebuzoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Quinapril is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Quinapril.
LacidipineQuinapril may increase the hypotensive activities of Lacidipine.
Lanthanum carbonateThe serum concentration of Quinapril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostLatanoprost may increase the hypotensive activities of Quinapril.
LeflunomideThe risk or severity of adverse effects can be increased when Quinapril is combined with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Quinapril.
LevobunololThe risk or severity of adverse effects can be increased when Quinapril is combined with Levobunolol.
LevodopaQuinapril may increase the orthostatic hypotensive activities of Levodopa.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Quinapril.
LisinoprilLisinopril may increase the hypotensive activities of Quinapril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Quinapril.
LofexidineQuinapril may increase the hypotensive activities of Lofexidine.
LornoxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Quinapril.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Quinapril.
LoxoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Lumiracoxib.
MacitentanQuinapril may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Quinapril is combined with Magnesium salicylate.
ManidipineQuinapril may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Quinapril.
MasoprocolThe risk or severity of adverse effects can be increased when Quinapril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Quinapril.
MecamylamineMecamylamine may increase the hypotensive activities of Quinapril.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Quinapril.
MetamizoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Metamizole.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Quinapril.
MethohexitalMethohexital may increase the hypotensive activities of Quinapril.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Quinapril.
MethyclothiazideThe risk or severity of adverse effects can be increased when Quinapril is combined with Methyclothiazide.
MethyldopaQuinapril may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Quinapril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Quinapril.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Quinapril.
MetipranololQuinapril may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Quinapril.
MetoprololMetoprolol may increase the hypotensive activities of Quinapril.
MibefradilQuinapril may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Quinapril.
MinaprineMinaprine may increase the hypotensive activities of Quinapril.
MinoxidilMinoxidil may increase the hypotensive activities of Quinapril.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Quinapril.
MoclobemideMoclobemide may increase the hypotensive activities of Quinapril.
MoexiprilMoexipril may increase the hypotensive activities of Quinapril.
MolsidomineMolsidomine may increase the hypotensive activities of Quinapril.
MoxonidineQuinapril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Nabumetone.
NadololQuinapril may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Quinapril.
NaftifineThe risk or severity of adverse effects can be increased when Quinapril is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Quinapril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Quinapril is combined with NCX 4016.
NebivololQuinapril may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Quinapril.
NepafenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Quinapril is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Quinapril.
NicardipineNicardipine may increase the hypotensive activities of Quinapril.
NicorandilNicorandil may increase the hypotensive activities of Quinapril.
NifedipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Quinapril is combined with Niflumic Acid.
NiguldipineQuinapril may increase the hypotensive activities of Niguldipine.
NilvadipineQuinapril may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Quinapril is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Quinapril.
NisoldipineNisoldipine may increase the hypotensive activities of Quinapril.
NitrendipineQuinapril may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quinapril.
NitroprussideNitroprusside may increase the hypotensive activities of Quinapril.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Quinapril.
ObinutuzumabQuinapril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Quinapril.
OlmesartanOlmesartan may increase the hypotensive activities of Quinapril.
OlopatadineThe risk or severity of adverse effects can be increased when Quinapril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Olsalazine.
OmapatrilatQuinapril may increase the hypotensive activities of Omapatrilat.
OrgoteinThe risk or severity of adverse effects can be increased when Quinapril is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxaprozin.
OxprenololQuinapril may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxyphenbutazone.
PapaverineThe risk or severity of adverse effects can be increased when Quinapril is combined with Papaverine.
ParecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Parecoxib.
PargylineQuinapril may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Quinapril.
PenbutololQuinapril may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Quinapril.
PentoliniumQuinapril may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Quinapril.
PerindoprilPerindopril may increase the hypotensive activities of Quinapril.
PethidineThe risk or severity of adverse effects can be increased when Quinapril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Quinapril.
PheniprazinePheniprazine may increase the hypotensive activities of Quinapril.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Quinapril.
PhenoxybenzamineQuinapril may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Quinapril.
PhentolaminePhentolamine may increase the hypotensive activities of Quinapril.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Quinapril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Quinapril.
PinacidilQuinapril may increase the hypotensive activities of Pinacidil.
PindololQuinapril may increase the hypotensive activities of Pindolol.
PiretanidePiretanide may increase the hypotensive activities of Quinapril.
PirfenidoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Quinapril.
PiroxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Quinapril.
PolythiazideQuinapril may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Quinapril.
PregabalinThe risk or severity of adverse effects can be increased when Quinapril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Quinapril.
PropacetamolThe risk or severity of adverse effects can be increased when Quinapril is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Quinapril.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Quinapril.
PTC299The risk or severity of adverse effects can be increased when Quinapril is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Quinapril is combined with Quetiapine.
QuinethazoneQuinethazone may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Quinapril.
RamiprilRamipril may increase the hypotensive activities of Quinapril.
RasagilineRasagiline may increase the hypotensive activities of Quinapril.
RemikirenRemikiren may increase the hypotensive activities of Quinapril.
RescinnamineQuinapril may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Quinapril.
ResveratrolThe risk or severity of adverse effects can be increased when Quinapril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Quinapril.
RiociguatQuinapril may increase the hypotensive activities of Riociguat.
RisperidoneQuinapril may increase the hypotensive activities of Risperidone.
RituximabQuinapril may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Rofecoxib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Quinapril.
SacubitrilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Quinapril.
SalicylamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Quinapril.
SalsalateThe risk or severity of adverse effects can be increased when Quinapril is combined with Salsalate.
SaprisartanQuinapril may increase the hypotensive activities of Saprisartan.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Quinapril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Quinapril.
SecobarbitalSecobarbital may increase the hypotensive activities of Quinapril.
SelegilineSelegiline may increase the hypotensive activities of Quinapril.
SelexipagQuinapril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Quinapril is combined with Seratrodast.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Quinapril.
SildenafilSildenafil may increase the antihypertensive activities of Quinapril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Quinapril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Quinapril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Quinapril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Quinapril.
SitaxentanQuinapril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Quinapril is combined with Sodium aurothiomalate.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Quinapril.
SpiraprilQuinapril may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Quinapril.
SRT501The risk or severity of adverse effects can be increased when Quinapril is combined with SRT501.
St. John's WortThe metabolism of Quinapril can be increased when combined with St. John's Wort.
SulfasalazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Quinapril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Quinapril.
TadalafilTadalafil may increase the antihypertensive activities of Quinapril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Quinapril.
TelmisartanQuinapril may increase the hypotensive activities of Telmisartan.
TemocaprilQuinapril may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Quinapril.
TenoxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Quinapril is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Quinapril is combined with Terazosin.
TeriflunomideThe risk or severity of adverse effects can be increased when Quinapril is combined with Teriflunomide.
TerlipressinQuinapril may increase the hypotensive activities of Terlipressin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Quinapril.
ThiamylalThiamylal may increase the hypotensive activities of Quinapril.
ThiopentalThiopental may increase the hypotensive activities of Quinapril.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Quinapril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Tiaprofenic acid.
TiboloneQuinapril may increase the hypotensive activities of Tibolone.
TicrynafenQuinapril may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Quinapril.
TinzaparinTinzaparin may increase the hyperkalemic activities of Quinapril.
TipranavirThe serum concentration of Quinapril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Quinapril.
TizanidineThe risk or severity of adverse effects can be increased when Quinapril is combined with Tizanidine.
TolazolineTolazoline may increase the hypotensive activities of Quinapril.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Quinapril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Quinapril.
TorasemideTorasemide may increase the hypotensive activities of Quinapril.
TrandolaprilTrandolapril may increase the hypotensive activities of Quinapril.
TranilastThe risk or severity of adverse effects can be increased when Quinapril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Quinapril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Quinapril.
TravoprostTravoprost may increase the hypotensive activities of Quinapril.
TreprostinilTreprostinil may increase the hypotensive activities of Quinapril.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Quinapril.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Quinapril.
TrichlormethiazideQuinapril may increase the hypotensive activities of Trichlormethiazide.
TrimazosinQuinapril may increase the hypotensive activities of Trimazosin.
TrimethaphanQuinapril may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Quinapril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Quinapril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Quinapril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Quinapril.
UnoprostoneQuinapril may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Quinapril.
VardenafilVardenafil may increase the antihypertensive activities of Quinapril.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Quinapril.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Quinapril.
XylometazolineQuinapril may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Quinapril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Quinapril.
ZileutonThe risk or severity of adverse effects can be increased when Quinapril is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Quinapril is combined with Zomepirac.
Food Interactions
  • Do not take with a high-fat meal.
  • Herbs that may attenuate the antihypertensive effect of quinapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of quinapril.
  • Quinapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Culy CR, Jarvis B: Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 2002;62(2):339-85. [PubMed:11817979 ]
  3. Klutchko S, Blankley CJ, Fleming RW, Hinkley JM, Werner AE, Nordin I, Holmes A, Hoefle ML, Cohen DM, Essenburg AD, et al.: Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. J Med Chem. 1986 Oct;29(10):1953-61. [PubMed:3020249 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23